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Dwyer 11-18-61*
FOR IMMEDIATE RELEASE
Dr. Carl L. Larson, director of the Stella Duncan Memorial Institute at 
Montana State University, has received a U. S. Public Health Service Research 
Career Award to continue basic research on tuberculosis, MSU officials announced.
The current award from the National Institute of Allergy and Infectious 
Diseases, effective December 1, will provide $18,717 for the coming year and is 
renewable for an additional year. The grant supplements a USPHS award of 
$83,105 in 1963 in support of Dr. Larson's work.
Dr. Larson, in collaboration with Dr. Edgar Ribi of the Rocky Mountain 
Laboratory in Hamilton, is working to perfect a vaccine that will give immunity 
to tuberculosis without producing sensitivity. Severed, months ago he and his 
colleague succeeded in producing a killed vaccine that proved effective and 
much less sensitizing than BCG vaccine in tests on laboratory animals. BCG 
has the disadvantage of being a live vaccine that produces a positive skin 
reaction to tuberculosis, Dr. Larson explained.
In sounding a note of cautious optimism about promising development of 
the research, Dr. Larson stressed that TB researchers speak of optimism in 
terms of years, not months. Their vaccine will not be tested on humans for 
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